The identification of safe, selective, potent, and effective PIM3 inhibitors provides a foundation for clinical translation and may have a significant clinical impact on the treatment of some solid and hematological cancers by offering new hope for patients with PIM3-driven cancers. The gene discussed is PIM3; the disease is hematopoietic and lymphoid cell neoplasm.